Syngene International Limited (SYNGENE.NS)
INR 727.0
(-0.29%)
INR 727.0
(-0.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 12.43 Billion INR | -46.68% |
| 2022 | 23.32 Billion INR | 32.71% |
| 2021 | 17.57 Billion INR | 12.49% |
| 2020 | 15.62 Billion INR | 14.87% |
| 2019 | 13.6 Billion INR | 14.86% |
| 2018 | 11.84 Billion INR | 25.62% |
| 2017 | 9.42 Billion INR | 11.22% |
| 2016 | 8.47 Billion INR | 9.35% |
| 2015 | 7.75 Billion INR | 28.41% |
| 2014 | 6.03 Billion INR | 21.79% |
| 2013 | 4.95 Billion INR | 25.72% |
| 2012 | 3.94 Billion INR | 33.12% |
| 2011 | 2.96 Billion INR | 29.91% |
| 2010 | 2.28 Billion INR | 17.1% |
| 2009 | 1.94 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.19 Billion INR | -41.66% |
| 2024 Q2 | 6.54 Billion INR | 33.09% |
| 2023 Q4 | 3.76 Billion INR | -38.95% |
| 2023 Q3 | 6.16 Billion INR | -4.17% |
| 2023 FY | 12.43 Billion INR | -46.68% |
| 2023 Q1 | 5.85 Billion INR | -16.46% |
| 2023 Q2 | 6.42 Billion INR | 9.84% |
| 2022 FY | 23.32 Billion INR | 32.71% |
| 2022 Q2 | 5.69 Billion INR | 17.75% |
| 2022 Q3 | 5.79 Billion INR | 1.86% |
| 2022 Q1 | 4.83 Billion INR | -1.93% |
| 2022 Q4 | 7 Billion INR | 20.86% |
| 2021 Q3 | 4.51 Billion INR | 2.01% |
| 2021 Q4 | 4.92 Billion INR | 9.12% |
| 2021 FY | 17.57 Billion INR | 12.49% |
| 2021 Q1 | 3.99 Billion INR | -0.5% |
| 2021 Q2 | 4.42 Billion INR | 10.7% |
| 2020 Q4 | 4.01 Billion INR | -7.99% |
| 2020 Q1 | 3.15 Billion INR | -4.68% |
| 2020 FY | 15.62 Billion INR | 14.87% |
| 2020 Q2 | 3.92 Billion INR | 24.29% |
| 2020 Q3 | 4.36 Billion INR | 11.43% |
| 2019 Q1 | 3.15 Billion INR | 14.98% |
| 2019 Q2 | 3.39 Billion INR | 7.64% |
| 2019 Q4 | 3.3 Billion INR | -11.64% |
| 2019 Q3 | 3.74 Billion INR | 10.31% |
| 2019 FY | 13.6 Billion INR | 14.86% |
| 2018 Q3 | 3.24 Billion INR | 5.25% |
| 2018 Q2 | 3.08 Billion INR | 11.22% |
| 2018 Q1 | 2.77 Billion INR | -2.22% |
| 2018 Q4 | 2.74 Billion INR | -15.47% |
| 2018 FY | 11.84 Billion INR | 25.62% |
| 2017 Q2 | 2.55 Billion INR | 15.06% |
| 2017 Q4 | 2.83 Billion INR | 0.93% |
| 2017 Q1 | 2.21 Billion INR | 5.37% |
| 2017 FY | 9.42 Billion INR | 11.22% |
| 2017 Q3 | 2.8 Billion INR | 10.07% |
| 2016 Q1 | 1.97 Billion INR | -18.13% |
| 2016 Q4 | 2.1 Billion INR | -9.54% |
| 2016 Q3 | 2.32 Billion INR | 7.63% |
| 2016 Q2 | 2.16 Billion INR | 9.3% |
| 2016 FY | 8.47 Billion INR | 9.35% |
| 2015 Q1 | 1.62 Billion INR | -9.81% |
| 2015 FY | 7.75 Billion INR | 28.41% |
| 2015 Q4 | 2.41 Billion INR | 24.73% |
| 2015 Q3 | 1.93 Billion INR | 6.15% |
| 2015 Q2 | 1.82 Billion INR | 12.09% |
| 2014 FY | 6.03 Billion INR | 21.79% |
| 2014 Q4 | 1.8 Billion INR | 17.28% |
| 2014 Q1 | 1.34 Billion INR | 0.0% |
| 2014 Q2 | 1.4 Billion INR | 4.61% |
| 2014 Q3 | 1.53 Billion INR | 9.23% |
| 2013 FY | 4.95 Billion INR | 25.72% |
| 2012 FY | 3.94 Billion INR | 33.12% |
| 2011 FY | 2.96 Billion INR | 29.91% |
| 2010 FY | 2.28 Billion INR | 17.1% |
| 2009 FY | 1.94 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 86.441% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | -293.706% |
| Concord Biotech Limited | 7.56 Billion INR | -64.427% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | -153.64% |
| Jubilant Ingrevia Limited | 9.16 Billion INR | -35.698% |
| Lyka Labs Limited | 145.95 Million INR | -8421.98% |
| Panacea Biotec Limited | 1.42 Billion INR | -771.191% |
| Piramal Pharma Limited | 24.47 Billion INR | 49.172% |
| SMS Lifesciences India Limited | 329.57 Million INR | -3673.94% |
| Supriya Lifescience Limited | 2.65 Billion INR | -369.04% |
| TAKE Solutions Limited | 183.42 Million INR | -6681.158% |
| Zota Health Care Limited | 332.52 Million INR | -3640.448% |